Equillium Announces Data From Phase 1b EQUIP Study In Patients With Uncontrolled Asthma; Says Study Achieved Primary Objective Of Safety And Tolerability, Demonstrated Rapid And Sustained Reduction In Levels Of Cell Surface CD6